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Results: During and after procedures we observed in 28% patients 
hypoxemia, in 23 % hemorrhage 250 cm3 and more, in 10% arytmias, 
in 5% patients we observed hypertension and in 2% patients developed 
after procedure respiratory failure and both patients were 24 hours 
on invasive ventilation. Two patients died due complications after 
procedure. Any complications we observed in 40% of all procedures. 
The procedure leads to improvement of symptoms in 80% patients. 
The difference in number of complications in patients with ASA III and 
with ASA IV was not statistically signiﬁcant (p=0.009).
Conclusions: Endobronchial treatment (electrosurgary and laser 
brochoscopy) leads to improvement of symptoms in 80% patients. 
This treatment procedure in general anesthesia with jet ventilation is 
therapeutic procedure with acceptable rate of complications in patients 
with endobronchial growth of malignancies and in patients with ASA 
classiﬁcation III and IV.
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Background: Bronchoscopy is usually performed under topical anes-
thesia with or without sedation to promote patient comfort and the ideal 
conditions for the physician to perform the examination. The objective 
of the study was to establish which anesthetic procedure used during 
ﬂexible bronchoscopy for lung cancer diagnostic has the lowest index 
of complications. 
Methods: This prospective randomized study analyzed 80 patients that 
underwent ﬂexible bronchoscopy for lung cancer diagnostic. Patients 
were randomly assigned to four groups of 20 patients each according 
to the anesthetic combination used: 200 mg topical lidocaine (LID 
group); 200 mg topical lidocaine and 2 mg/kg propofol (PPF group); 
200 mg topical lidocaine and 20 mcg/kg alfentanil (ALF group); or 200 
mg topical lidocaine and 0.05 mg/kg midazolam (MID group). Scores 
were assigned to patients according to the different variables observed 
during the bronchoscopic procedure; the lower the score, the lower the 
complication index. 
Results: Results of the composite score (mean and standard devia-
tion) for the evaluation of the variables observed during ﬂexible 
bronchoscopy were 4.6„b3.9 for the PPF group, 7.9„b6.6 for the ALF 
group, 10.0„b4.5 for the LID group, and 11.3„b5.8 for the MID group 
(p=0.001).
Conclusions: Results showed that the combination of propofol and 
topical lidocaine was a superior anesthetic method for ﬂexible bron-
choscopy than lidocaine alone or in association with midazolam or 
alfentanil.
Clinical Implications: The choice of an effective and low morbidity 
anesthetic method is basic for the success of a diagnostic ﬂexible bron-
choscopy. This study it demonstrated the superiority of the association 
of propofol and topic lidocaine in the anesthesia for ﬂexible bronchos-
copy in lung cancer patients.
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Background: Adenocarcinoma of the lung is more frequent in females 
than in males and the association with smoking is less pronounced than 
for the other histological subtypes of lung cancer. Thus other factors 
than smoking may be involved in the carcinogenesis of lung cancer. 
Estrogen induction of cellproliferation has been found in for example 
breast adenocarcinoma and since estrogen receptors (ER) have been 
demonstrated in lung tumours, a similar role of estrogens in the devel-
opment of lung cancer has been suggested. 
Whereas ERalfa plays a key role in adenocarcinomas of the breast, sev-
eral studies indicate a more predominant role of ERbeta in lung cancer. 
We examined the expression of ERalfa, ERbeta, and Progesterone in a 
well deﬁned Danish cohort of patients with NSCLC with more than 15 
years of follow up, and related the results to gender and survival. 
Methods: Parafﬁn embedded, histological material was collected from 
104 patients (71 men and 33 women), operated in the period 1989-1992 
for NSCLC (56 squamous cell carcinomas, 40 adenocarcinomas and 8 
large cell carcinomas). Sixtythree patients were in stage I, 14 patients 
in stage II, 24 patients in stage IIIA, and 3 patients in stage IIIB.
ERalfa (clone 1D5, DAKO), ERbeta (clone PPG5/10, DAKO) and Pro-
gesterone (clone PgR 636, DAKO) were immunohistochemically ana-
lyzed. Staining frequency and intensity was scored semiquantitatively. 
A tumour was deﬁned as positive when more than 10% of the tumour 
cells were positive with at least a weak nuclear staining. Kaplan-Meier 
survival curves were generated to evaluate the signiﬁcance of ERalfa, 
ERbeta and Progesterone expression for the prognosis. 
Results: ERbeta positivity was demonstrated in 69% (72 of 104) of the 
tumours. There was no statistically signiﬁcant correlation between ER-
beta positivity and age, sex, stage, or histology. After adjusting for sex, 
age, stage at diagnosis and histology there was no difference in survival 
between subjects with ERbeta-positive and ERbeta-negative tumours. 
Analysis was repeated after stratifying by sex. Women with ERbeta-
negative tumours had a non-signiﬁcant (p=0.26) decrease in mortality 
compared with women with ERbeta positive tumours. In contrast, men 
with ERbeta positive tumours had a reduced mortality (p=0.03) com-
pared to men with ERbeta negative tumours (see Figure). 
